Results 211 to 220 of about 82,196 (246)
Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl.
JAMA Netw OpenSuen LW +10 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The effects of buprenorphine in buprenorphine-maintained volunteers
Psychopharmacology, 1997Buprenorphine is a mu opioid partial agonist currently used as an analgesic, and being developed for the treatment of opioid dependence. The purpose of this study was to determine the abuse liability of parenteral buprenorphine in volunteers maintained on daily sublingual (SL) buprenorphine (8 mg).
Eric C. Strain +4 more
openaire +3 more sources
Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia
Drug and Alcohol Dependence, 2010Buprenorphine maintenance is efficacious for treating opioid dependence, but problems with diversion and misuse of buprenorphine (BUP) may limit its acceptability and dissemination. The buprenorphine/naloxone combination tablet (BNX) was developed to reduce potential problems with diversion and abuse.
Richard S. Schottenfeld +3 more
openaire +2 more sources
The radioimmunoassay of buprenorphine
European Journal of Clinical Pharmacology, 1980Antisera to buprenorphine were obtained in rabbits immunised with 3-0-carboxymethylbuprenorphine and N-hemisuccinyl-norbuprenorphine conjugated to bovine serum albumin. Using the latter antiserum and tritium labelled buprenorphine a radioimmunoassay have good accuracy and precision was developed for concentrations as low as 50 picograms in 1 ml of ...
M. R. D. Bennett +6 more
openaire +3 more sources
Drug and Alcohol Dependence, 1985
Buprenorphine is a mixed agonist-antagonist with high affinity at both mu and kappa opiate receptors. Its pharmacological profile is determined primarily by partial agonism at mu-receptors and unusually slow kinetics at these receptors. Its intrinsic activity is such that in nearly all clinical situations it is as effective an analgesic as morphine ...
openaire +2 more sources
Buprenorphine is a mixed agonist-antagonist with high affinity at both mu and kappa opiate receptors. Its pharmacological profile is determined primarily by partial agonism at mu-receptors and unusually slow kinetics at these receptors. Its intrinsic activity is such that in nearly all clinical situations it is as effective an analgesic as morphine ...
openaire +2 more sources
Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine
Psychopharmacology, 2001Buprenorphine is an opioid agonist-antagonist used in the treatment of opioid dependence. Naloxone has been combined with buprenorphine to decrease the parenteral abuse potential of buprenorphine. This addition of naloxone may also confer further opioid blockade efficacy.To test the opioid blockade efficacy of sublingual buprenorphine/naloxone versus ...
Sharon L. Walsh +2 more
openaire +3 more sources
Clinical Pharmacology and Therapeutics, 1980
Buprenorphine kinetics was determined in surgical patients using radioimmunoassay. Buprenorphine was measured in the plasma of 24 patients who had received 0.3 mg buprenorphine intraoperatively. After 3 hr 10 of these patients then received a further 0.3 mg buprenorphine intravenously for postoperative pain relief, and 11 patients were given 0.3 mg ...
R E, Bullingham +3 more
openaire +2 more sources
Buprenorphine kinetics was determined in surgical patients using radioimmunoassay. Buprenorphine was measured in the plasma of 24 patients who had received 0.3 mg buprenorphine intraoperatively. After 3 hr 10 of these patients then received a further 0.3 mg buprenorphine intravenously for postoperative pain relief, and 11 patients were given 0.3 mg ...
R E, Bullingham +3 more
openaire +2 more sources
Drugs, 2003
Buprenorphine is a low molecular weight, lipophilic, opioid analgesic. Recently, a transdermal matrix patch formulation of buprenorphine has become available in three dosage strengths designed to release buprenorphine at 35, 52.5 and 70 micro g/h over a 72-hour period. At least satisfactory analgesia with minimal requirement for rescue medication (
Hannah C, Evans, Stephanie E, Easthope
openaire +2 more sources
Buprenorphine is a low molecular weight, lipophilic, opioid analgesic. Recently, a transdermal matrix patch formulation of buprenorphine has become available in three dosage strengths designed to release buprenorphine at 35, 52.5 and 70 micro g/h over a 72-hour period. At least satisfactory analgesia with minimal requirement for rescue medication (
Hannah C, Evans, Stephanie E, Easthope
openaire +2 more sources